Fennec Pharmaceuticals Inc. (NASDAQ: FENC)
$5.4800
+0.7600 ( +17.09% ) 259.7K
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Market Data
Open
$5.4800
Previous close
$4.7200
Volume
259.7K
Market cap
$147.04M
Day range
$4.6810 - $5.5550
52 week range
$3.9600 - $11.9200
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 16 | Feb 29, 2024 |
| 8-k | 8K-related | 16 | Feb 02, 2024 |
| 4 | Insider transactions | 1 | Jan 05, 2024 |
| 4 | Insider transactions | 1 | Dec 29, 2023 |
| 4 | Insider transactions | 1 | Dec 28, 2023 |
| 8-k | 8K-related | 18 | Dec 06, 2023 |
| 4 | Insider transactions | 1 | Nov 20, 2023 |
| 4 | Insider transactions | 1 | Nov 16, 2023 |
| 4 | Insider transactions | 1 | Nov 09, 2023 |
| 10-q | Quarterly Reports | 60 | Nov 09, 2023 |